Fig. 1

Maraba delivery targets ovarian tumors for oncolysis and boosts vaccine-elicited anti-tumor T cell responses. a OVA-specific CD8⁺ T cells were assessed in the blood of untreated (■) or MIS416 Vax treated () mice on d10 post vaccination (n = 10–20). b Representative FACs plots from a single mouse treated with MIS416 Vax showing % OVA-specific CD8⁺ T cells in the PBL and peritoneal TME c IE9-mp1 tumor progression was assessed based on increasing abdominal circumference of mice following vaccination (n = 5). d IE9-mp1 cells were infected with MRB at increasing MOI and cell viability assessed 24 h post infection. e Titer of replicating MRB virus in tumor tissue over time following IV (■), IP (), or IV/IP () virus delivery (n = 3 mice/group/time point). f Tumor load was assessed by bioluminescent imaging of ID8-FLUC tumor-bearing mice at indicated time points following virus delivery (n = 4–5). g Representative FACs plots depicting OVA-specific CD8⁺ T cell responses combining MIS416 Vax with MRB-OVA boosting by different routes. Data presented as mean ± SEM. Data in c is from one representative experiment and (d) compiled from 3 independent experiments